Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -4 of 4 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				CAT-8015-1002 NCT00457860


2.		Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				CAT-8015-1001 NCT00462189

Last Modified: 10/22/2007 First Published: 8/25/2007


3.		Phase I Study of Anti-CD22 Immunotoxin CAT-8015 in Patients with Relapsed or Refractory CD22-positive B-Cell Non-Hodgkin Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				NCI-07-C-0200 07-C-0200, NCI-P7118, CAT-8015-1003, NCT00522483


4.		CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				6 months to 25 years				NCI, Pharmaceutical / Industry				CAT-8015-1004 NCT00659425

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute